Filing Flows › Orchestra BioMed Holdings (OBIO) › Q2 2026 › vs Q1 2026
Orchestra BioMed Holdings (OBIO) Q2 2026 vs Q1 2026 (quarter over quarter)
Orchestra BioMed Holdings's revenue fell $22K (-20%) from $110K in Q1 2026 to $88K in Q2 2026.
Orchestra BioMed Holdings, Q2 2026: revenue $88K (-90% year over year), net loss $23.8M, operating cash flow −$19.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $88K | $110K | −$22K | -20% |
| Net loss | $23.8M | $20.7M | $3.1M | +15% |
| Costs & expenses | $23.8M | $22.2M | $1.7M | +7% |
| Operating costs | $22.4M | $22.2M | $258K | +1% |
| Interest & other, net | $1.4M | −$1.4M | $2.8M | — |
| Cost of revenue | $25K | $32K | −$7K | -22% |
| Research & development | $16.6M | $15.8M | $809K | +5% |
| SG&A | $5.8M | $6.4M | −$544K | -9% |
| Operating cash sources | $23.8M | $20.7M | $3.1M | +15% |
| Depreciation & amortization | $96K | $90K | $6K | +7% |
| Share-based compensation | $2.5M | $2.9M | −$346K | -12% |
| Working capital & other | $1.8M | −$4.4M | $6.2M | — |
| Cash used in operations | $19.3M | $22.2M | −$2.8M | -13% |
| Net loss absorbed | $23.8M | $20.7M | $3.1M | +15% |
Questions
How much did Orchestra BioMed Holdings's revenue grow quarter over quarter in Q2 2026?
Orchestra BioMed Holdings's revenue fell $22K (-20%) from $110K in Q1 2026 to $88K in Q2 2026.